The drumbeat of innovation in the heart valves space continues as companies pursue next-generation devices for easier implantation, to improve durability and to treat younger patients. Even though ...

South San Francisco-based Trex Bio Inc. priced its IPO of about 8.3 million shares at $14 per share for about $116.7 million to finance efforts taking aim at a pair of targets hardly unfamiliar to the ...

Ono Pharmaceutical Co. Ltd. is paying $100 million up front to gain select Asian rights to Biohaven Ltd.’s small-molecule IgG degrader portfolio, including in Japan, South Korea and Taiwan, as it ...

Neurizon Therapeutics Ltd. has advanced NUZ-001 (monepantel) from a 12-patient proof-of-concept study into a fully enrolled, ...

Several initiatives the U.S. Department of Health and Human Services (HHS) announced Oct. 8 continue to shift the government’s vaccine focus from disease prevention to vaccine harm. Strengthening “how ...

In the last five years, public markets in Europe have been a no-go area for biotechs, and for U.K. companies the situation is dire, with the way barred to new entrants and a lack of liquidity leading ...

Persistent mycobacterial infections may depend on senescent macrophages that provide a long-term intracellular refuge to ...

Simcere Pharmaceutical Co. Ltd. has divulged bicyclic compounds acting as lysosomal acid glucosylceramidase (GBA; β-glucocerebrosidase) positive allosteric modulators reported to be useful for the ...

Radiopharmaceuticals have been used for a long time for diagnostics, but radiopharma therapies are entering a new era in which they are becoming widely accepted as a key tool in the oncology ...

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Viatris Inc. plans to discuss the buyout of Pacira Biosciences Inc. during its third-quarter earnings call Nov. 5, but the ...